Kymera Therapeutics (KYMR) UBS Targeted Protein Degradation Day 2024 summary

Platform and discovery capabilities

• Focus on undrugged or poorly drugged targets where protein degradation is the optimal approach.

• Internal development of all chemical matter, with advanced hit-finding and structural biology capabilities.

• Four clinical programs launched in less than four years, with high translational fidelity in PK, PD, safety, and efficacy.

• Annual goal to file at least one new IND, with consistent pipeline expansion expected.

IRAK4 program and clinical updates

• Study expansion adds more dose levels to accelerate development, making this the only phase 2 study before phase 3.

• Interim analysis by Sanofi led to further investment, indicating a key development milestone was met.

• High confidence in IRAK4’s relevance for a broad range of inflammatory diseases, supported by robust preclinical and early clinical data.

• Additional indications such as respiratory, GI, and rheumatology are under consideration, pending partner decisions.

• No significant safety concerns observed in preclinical and phase 1 data.

STAT6 and other pipeline programs

• STAT6 is targeted as a selective transcription factor for Th2 diseases, aiming for biologics-like efficacy with an oral degrader.

• Phase 1 design for STAT6 will focus on PK, PD, safety, and cytokine modulation, with data expected in the first half of next year.

• Extensive preclinical safety data for STAT6 shows no adverse events, supporting confidence in clinical safety.

• STAT3 in oncology is showing promising signals in Hodgkin’s lymphoma, with full phase 1A data expected by year-end.

• MDM2 and TYK2 programs continue dose escalation, with a focus on demonstrating differentiated efficacy profiles.